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Summary
Objective: Histomorphometric study on cartilage samples taken from osteoarthritic human knees before and 6 months after intraarticular
injections of a specific fraction (500–730 kDa) of hyaluronan. The results obtained with hyaluronan were compared with the results of
methylprednisolone acetate treatment.
Methods: Twenty-four subjects with primary osteoarthritis (OA) of the knee were considered. Eleven patients were treated with Hyaluronan
(Hyalgan®, 20 mg/2 ml once a week for 5 weeks) and 13 with methylprednisolone (Depo-Medrol®, 40 mg/1 ml once a week for 3 weeks). At
the time of baseline and after 6 months from the start of treatment, biopsies of cartilage were taken and processed for electron microscopy.
Articular surface morphology, territorial matrix, chondrocyte number and ultrastructure were characterized by a set of morphometric
parameters. Samples from 19 informed patients showing no arthroscopic sign of OA were also used for comparison.
Results: Six months after hyaluronan treatment a significant reconstitution of the superficial layer were observed together with an
improvement in chondrocyte density and territorial matrix appearance. Furthermore, chondrocytes appeared significantly improved in their
metabolism, as indicated by the increased extension of the synthetic structures and mitochondria with respect to the organelles having
catabolic or storage functions. Hyaluronan treatment produced results that were significantly superior to those delivered with Methylpred-
nisolone in almost all the morphometric estimators.
Conclusions: These results cannot be explained simply by temporary restoration of the synovial fluid viscoelasticity, and provide further
evidence that the specific fraction of hyaluronan used in this study is a useful tool in OA treatment, with a potential structure-modifying
activity. © 2001 OsteoArthritis Research Society International
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Osteoarthritis (OA) is presently regarded as a disease
process affecting the entire joint1, originated by a variety of
mechanisms and resulting in a progressive degradation of
the articular cartilage. Current therapy for OA is capable of
alleviating the symptoms but no agent has, as yet, been
definitively shown to slow down the progression of cartilage
damage. Significant resources are now being dedicated to
the search for drugs characterized by structure-modifying
activity, i.e. able to slow down the rate of cartilage degen-
eration and/or enhance that of cartilage repair2,3.
Hyaluronic acid (HA) is a natural molecule playing a
pivotal role in all the regions of the joint. It is actively
synthesized by the synoviocytes and it determines the371viscoelastic properties of the synovial fluid. In the cartilage,
permanently complexed with proteoglycans, HA is essen-
tial in mantaining the structural and functional characteris-
tics of this tissue. In addition, HA, either free or weakly
associated with short proteoglycan structures, contributes
to the formation of an amorphous layer about 0.6 m thick,
covering the articular surface of the cartilage4, contributing
to the boundary lubrication mechanism in conditions of
extreme loading5 and partially protecting the tissue from
the penetration of inflammatory cells and lytic enzymes.
It is well known that in pathological processes, such as
OA and rheumatoid arthritis (RA) the molecular weight of
the HA in the synovial fluid can be reduced by an order of
magnitude (from 106 to 105 Da) and its concentration is
also reduced mainly due to the accumulation in the
joint cavity of liquid derived from the inflamed synovial
vessels6,7. The result is a reduction in the viscoelasticity of
the fluid and an increased susceptibility of cartilage to
breakdown.
To counteract this process a therapeutic strategy based
on the use of intraarticular injections of exogenous HA
started in the late 1960s8,9. Since then a large number of
studies has been published demonstrating the positive and
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joint diseases10–20.
Very recently, the effects of HA therapy on human joint
tissues have been directly monitored using arthroscopy
and histomorphometric analysis of biopsies21,22. The
results documented that HA treatment induced an improve-
ment of several structural features of both synovial mem-
brane and cartilage, opening the possibility for HA to be a
candidate structure (disease-) modifying drug.
In order to further study the effects of a specific fraction
of HA (500–730 kDa) on the structure of joint tissues in OA,
we carried out a histological and electron microscopy study
on cartilage samples taken from osteoarthritic human
knees before and 6 months after local injections of
Hyalgan® (FIDIA SpA, Italy). The results obtained with
Hyalgan were compared with the results of methyl-
prednisolone acetate (Depo-Medrol®) treatment.Materials and methods
STUDY DESIGN
The study is focused on biopsy samples coming from a
clinical trial carried out on 50 patients, aged from 38 to 73
years, with primary OA of the knee. The trial was a
6-month, randomized, controlled study, in which OA was
diagnosed following the criteria of the American College of
Rheumatology23 and was arthroscopically confirmed.
Patients judged uncontrollable or unreliable, those with
severe concomitant diseases making assessment of the
result difficult, those receiving therapies during the previous
3 months (apart from oral administration of non-steroid
antiinflammatory drugs) and women in pregnancy or breast
feeding were excluded from the trial. Consecutive out-
patients with clinically and radiologically diagnosed uni-
lateral or bilateral OA of the knee (Kellgren–Lawrence
grades I–III) were admitted to the study. The rate of
acceptance to enter the study was 60%. Patients judged
eligible underwent a first knee arthroscopy during which
biopsies of cartilage were obtained.
Half of the recruited patients were to be treated with
hyaluronan (Hyalgan®, FIDIA SpA) and half with methyl-
prednisolone (Depo-Medrol®, Pharmacia & Upjohn).
Patients were recruited into one of the two treatment
groups following a randomization scheme generated by
computer. In presence of bilateral OA, the more severely
affected knee was selected for treatment.
Within 15–20 days of the arthroscopic inspection, all
these patients had a baseline visit with collection of blood
and urine samples for routine laboratory assessments.
They then started on a course of intraarticular injections of
2 ml Hyalgan® (10 mg/ml 500–730,000 MW hyaluronan in
saline) once a week for 5 weeks, or 1 ml Depo-Medrol®
(40 mg/ml 6-methylprednisolone acetate in saline) once a
week for 3 weeks.
On days 7, 14, 21, 28, 35, 60, 120 and 180 clinical
parameters were assessed and blood and urine samples
collected for laboratory analysis. During this period no
patient of either group took analgesic drugs or used
NSAIDs regularly. On day 180 each patient underwent a
second arthroscopic examination and, if the patient agreed,
a second biopsy for morphological analysis was performed.
Only cartilage samples coming from patients with primary
OA, who underwent both basal and final cartilage sampling
(Table I) were considered for the present study.A normal control group of cartilage samples was also
obtained from 19 subjects who underwent arthroscopy for
pain, but did not reveal any sign of either OA or RA.
The trial was approved by the Ethical Committee of the
Ospedale Maggiore of Bologna. Written informed consent
for treatment, arthroscopic inspections and sampling was
obtained from all patients.Table I
Profile of patients
Hyaluronan Methylprednisolone
No. of subjects 11 13
Male 4 7
Female 7 6
Age (mean±S.E.M.) 51.5±2.8 57.0±1.7ARTHROSCOPIC EXAMINATION AND BIOPSY SAMPLING
Microarthroscopy was always performed by the same
investigator, using Hamou-Storz and Microview-Wolf
arthroscopes equipped with a ×1 to ×150 selection of
magnification and automatic focus control. Local anesthe-
sia was induced by injections of 2 ml 2% Mepivacaine-HCl
without a vasoconstrictor. The endoscope was introduced
antero-laterally keeping the knee flexed at an angle of 30°.
Intermittent irrigation with Ringer’s acetate was used to
mantain the intraarticular pressure around 80 mm Hg
and to optimize the degree of distension of the joint cavity.
Three millilitres of 1% methylene blue in aqueous solution
(pH 4.5) was injected into the joint cavity, left for 5 min and
then exhaustively washed out with saline.
Biopsies of the articular cartilage were only taken from
those patients with arthroscopic grade II lesions (i.e. carti-
lage marked by fibrillation, fissures and a velvety appear-
ance) according to a series of previously described
standardized procedures22. In each patient the area cho-
sen for sampling was the tissue compartment presenting at
baseline the lesion with the greatest superficial extension.
Tissue samples were taken from the edge of the lesion,
which was easily identified by the more intense staining
with methylene blue of the damaged area when compared
with healthy tissue.
Because the same tissue region had to be sampled
again during the final arthroscopic examination on day 180,
to determine the precise sampling area a graded needle-
probe was inserted under continuous arthroscopic control,
using an independent route of access depending on the
tissue compartment involved.
For the medial and lateral femoral condyles, the probe
was introduced at the point of intersection of a straight line
tangential to the anterior margin of the collateral ligament
with the synovio-meniscus junction. It was advanced along
the femoral condyle tangent until the apex of the probe
coincided with the area chosen for sampling. For the medial
and lateral tibial plateau, the route of insertion of the probe
was the same as that described for the medial femoral
condyle. The probe was advanced along the femoral con-
dyle, tangentially passing the tibial spine until the apex
coincided with the area chosen for sampling. For the
patella, the probe was inserted medially into the femoro-
patellar space, advancing along a line coinciding with the
median transverse axis of the patella until the apex co-
incided with the chosen sampling zone. The distribution of
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treatment groups.
Cartilage specimens of the normal control group were
taken from the middle of the edge between the condylar
articular cartilage and the intercondylar notch medial sur-
faces. Biopsies were numbered according to a randomiza-
tion list, processed and examined without any information
apart from the identification number.SPECIMEN PREPARATION
After excision cartilage samples were immediately
dipped in 1% glutaraldehyde (Fluka AG, Buchs,
Switzerland) and Tyrode’s physiological solution pH 7.2
and then cut under a stereomicroscope in small blocks,
less then 0.5 mm wide, taking care to maintain the whole
thickness of the cartilage in each fragment. Samples were
then fixed by 2.5% glutaraldehyde in Tyrode’s pH 7.2, in the
presence of 0.1% toluidine blue O (Serva Feinbiochemica,
Heidelberg, Germany), for 24 h at 4°C and then by 1%
osmium tetroxide (Fluka AG, Buchs, Switzerland) in
Tyrode’s pH 7.2, containing 0.05% toluidine blue O, for 2 h
at room temperature. After dehydration in ethanol and
propilene oxide, specimens were embedded in Spurr resin
(Polysciences Inc., Warrington, PA), taking care to orient
them in order to have on the same section the whole
thickness of the cartilage. 0.5 m-thick sections were
stained with 0.1% toluidine blue O in 1% Na2B4O7
and used for light microscopy (Phomi III, Carl Zeiss,
Oberkochen, Germany), ultrathin sections (70–80 nm thick)
were collected on copper grids and stained with uranil
acetate and lead citrate for transmission electron
microscopy (CM12, Philips, Eindhoven, The Netherlands).MORPHOMETRY AND STATISTICAL ANALYSIS
At least three random blocks per biopsy were considered
for the morphometric analysis and analysed under blind
conditions. A set of parameters was determined in the
tangential layer (or Zone I) and in the intermediate layer (or
Zone II) of the articular cartilage24 by using a computer
assisted image analysis system (IBAS, Kontron, Eching,
Germany). At the light microscopy level the number of
chondrocytes per unit volume and the volume density of the
cells were estimated.
The chondrocyte numerical density was obtained
according to the disector method, in which, instead of a
single sectioning plane, two parallel planes separated by a
known distance (3 m in our study, since we analysed the
first and the seventh section of a consecutive series, each
section being 0.5 m in thickness) are used to count the
cells25. Volume density of the chondrocytes was estimated
by planimetry as the ratio between the area occupied by
cell profiles and the sampled tissue area. From these basic
estimators the mean cell volume was calculated.
A quantitative measurement of the articular surface
roughness was also performed at the light microscopy
level. Surface roughness is the degree of deviation of the
surface profile from an idealized smooth surface and can
be evaluated on tissue sections by calculating, from the
digitized surface profile, the parameter RMS (root mean
square roughness) as indicated by Hacker et al.26.
In order to estimate the numerical density of metaboli-
cally active chondrocytes, the percentage of necrotic cell
profiles was evaluated directly at the transmission electronmicroscope by a systematic sampling of both Zone I and
Zone II at a magnification of ×3000.
The quantitative characterization of the chondrocyte
ultrastructure was performed according to the approach
originally proposed by Annefeld27. Micrographs of 10 cell
profiles per block in both Zone I and Zone II were taken at
a magnification of ×17000 and the volume fraction occu-
pied by the components of the chondrocyte anabolic
(Rough Endoplasmic Reticulum (RER), Golgi apparatus,
Mitochondria) and catabolic systems (lysosomes, fatty
acid vacuoles, glycogen, intermediate filaments) was then
estimated by point counting28.
The mean thickness of the superficial amorphous layer of
the cartilage was also measured at the electron microscopy
level and its compactness assessed for each block by using
the following semiquantitative scale (see Fig. 1): 0, absent;
1, fragmented; 2, discontinuous; 3, compact.
An evaluation of the presence of anomalous territorial
matrix (see Ghadially24) was obtained in Zone I by record-
ing the eventual occurence of this feature on two ultrathin
sections, taken at a distance greater than the mean
chondrocyte diameter (∼12 m) from each of the consid-
ered blocks for a total of at least six observations per
biopsy. The frequency of occurrence was then estimated
for each subject. The difference between the frequency
observed after treatment and that at baseline was used to
establish whether each patient showed improvement,
worsening or no changes of the parameter.
Following the same approach, the occurrence in the
general matrix of atypical collagen fibers (thicker or
branched fibrils24) was also estimated.
The basal/final sequence and the type of treatment were
matched at the end of the study, when data were processed
by a computerized program for statistical analysis (SAS
Institute, Cary, NC, U.S.A.). Comparisons of quantitative
parameters within groups (final vs basal) were performed
by non-parametric tests (Sign Rank Test), while the ANOVA
was used to assess differences between treatments.
Fisher’s exact test was used for the analysis of data
concerning the territorial matrix and the collagen fibers.
Given the relatively low number of subjects who consented
to both biopsies, in order to provide the adequate power to
the statistical tests 0.10 was considered statistically
significant29.ResultsBASELINE OBSERVATIONS
The structural appearance of articular cartilage tissue in
semithin sections cut perpendicular to the joint surface is
illustrated in Fig. 2(b). The articular surface showed fibril-
lations and fissures and the cell density appeared to be
decreased in both zone I and zone II with respect to a
normal control sample [Fig. 2(a)].
When observed at the electron microscopy level, all the
baseline samples from this study presented detectable
modifications of the superficial amorphous layer which
covers the free articular surface. The modifications con-
cerned both the thickness and the compactness of this
layer (which appeared discontinuous or fragmented into
granules). In about 30% of the biopsies taken at baseline it
was completely absent.
The presence in zone I of anomalous territorial matrix
was observed in more than 70% of the baseline biopsies: a
number of chondrocyte profiles appeared lying in unusually
374 D. D. Guidolin et al.: Hyaluronan effects on cartilage in OAFig. 1. A series of electron micrographs (primary magnification: ×28000) illustrating different degrees of damage of the superficial amorphous
layer of the cartilage. The normal compact appearance is shown in (A). In (B) it exhibits discontinuities and in (C) it appears fragmented in
granules. A complete absence of the structure is illustrated in (D).large amounts of territorial matrix, which itself was atypical
(compared with normal samples) in that it was packed with
fine collagen fibrils.
In about 90% of the baseline samples atypical collagen
fibers were observed in the general matrix. They appeared
as short lengths of thicker (∼250 nm) fibrils wich stained
much more intensely than native collagen fibrils. Collagen
fibers with a branching appearance were also frequently
detected.
The qualitative observations were confirmed by the mor-
phometric evaluations (Table II) and no significant differ-
ences were detected at baseline between the treatment
groups.
The articular surface roughness, as measured by the
RMS parameter, increased in OA samples by a factor of ∼4
(P<0.01) with respect to the value observed in normaltissue samples. Furthermore, the superficial amorphous
layer showed a strong decrease of the compactness
score and a reduction of the mean thickness of about
60% (P<0.01) when measured in baseline biopsy samples
coming from OA patients.
In baseline biopsies a variable percentage (from 10% up
to 50%) of chondrocyte profiles visible on sections corre-
sponded to degenerating or necrotic cells. As a conse-
quence, the OA tissue exhibited, when compared to the
normal control samples, a decrease of more than 40%
(P<0.01) in the number of living chondrocytes in both zone
I and zone II.
No significant differences were observed in the mean cell
volume between samples coming from OA and non-OA
patients. The ultrastructure of the chondrocytes, however,
underwent significant changes in OA compared to controls
Osteoarthritis and Cartilage Vol. 9, No. 4 375Fig. 2. Photomicrographs (primary magnification: ×20) illustrating the light microscopy appearance of the cartilage samples coming
respectively from a non-OA patient (A) and from an osteoarthritic subject at baseline (B) and 6 months after hyaluronan treatment (C).(Fig. 3). As reported in Table II, a decrease of the cell
volume occupied by the organelles responsible for the
anabolic metabolism and a correspondent increase of thevolume of the structures having catabolic or storage func-
tions were observed in the chondrocytes belonging to OA
subjects.
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At the final control (on day 180) a reduction of the typical
osteoarthritic lesions was observed in about 80% of the
second biopsies. Some fissure and fibrillations of the articu-
lar surface were still present, but the RMS parameter had
improved, exhibiting changes to the value estimated in
normal control samples (Table III). When compared with
the baseline conditions, however, this change failed to
reach the statistical significance in the MP treated group
(P=0.275) while a statistically significant difference was
observed in the HA treated subjects (P=0.064).
The superficial amorphous layer (Table III) appeared
improved in its structure with both treatments. The com-
pactness score exhibited more pronounced changes
towards normality after HA treatment (P=0.005) compared
to MP (P=0.758), but the difference between groups was
not statistically significant. Furthermore, only in the HA
treated patients was a significant recovery of the thickness
of the amorphous layer observed with respect to the basal
situation (P=0.002) and the difference between the two
treatments was also statistically significant (P=0.019).
The numerical density of metabolically active chondro-
cytes (Fig. 4), which was strongly reduced at the basal
inspection, appeared partially restored after both treat-
ments. In zone I this recovery reached statistical signifi-
cance only in the HA treated patients (P=0.004), while in
zone II the increase exhibited by the parameter when
compared with the baseline was significant with both treat-
ments, HA being more effective than MP (P=0.002 and
P=0.049 respectively).
No changes were detected after either treatment in the
mean volume of the chondrocytes either in zone I or in
zone II. However, a significant increase of the cell volumeoccupied by structures belonging to the anabolic system
and a correspondent significant decrease of the one occu-
pied by organelles with catabolic or storage functions
occurred after HA treatment in both zone I and zone II,
approaching the reference values observed in the control
group. For all these parameters HA proved more effective
than MP. As shown in Fig. 5, for most of the ultrastructural
parameters significant differences between the two
treatments were also observed.
The frequency of occurrence of atypical collagen fibers
decreased after treatment. In about 50% of the second
biopsies this parameter appeared improved, with no signifi-
cant difference between the two groups.
A significant difference between treatments (P=0.02)
was detected when the territorial matrix was considered
(Table IV). This parameter showed an improvement in
80% of the biopsies coming from HA treated patients, while
only 30% of the MP treated subjects improved and about
50% of them showed a worsening of the territorial matrix
appearance.Table II
Morphometric estimators in the articular cartilage of the human knee in primary osteoarthritis at baseline





RMS 3.13±0.37 2.41±0.42 0.62±0.06 P=0.0943 P=0.0001
Superficial layer:
Compactness (score) 0.70±0.18 0.60±0.26 2.26±0.19 P=0.7670 P=0.0001
Thickness (m) 0.22±0.07 0.21±0.07 0.59±0.04 P=0.8589 P=0.0001
Zone I chondrocytes:
Numerical density (×104 cells/mm3) 0.91±0.14 1.07±0.17 1.84±0.09 P=0.4218 P=0.0001
Cell volume (m3) 783±41 735±29 787±38 P=0.4355 P=0.5330
RER (m3) 29.7±5 35.1±6 69.8±5 P=0.5218 P=0.0001
Golgi (m3) 12.1±2 10.8±3 30.2±4 P=0.8277 P=0.0002
Mitochondria (m3) 8.5±1 7.8±0.7 16.7±1 P=0.7011 P=0.0001
Lysosomes (m3) 3.8±0.8 3.6±0.6 1.24±0.2 P=0.8400 P=0.0001
Glycogen (m3) 18.6±4 21.0±4 8.1±2 P=0.6286 P=0.0032
Lipid vacuoles (m3) 10.7±3 17.9±5 3.8±1 P=0.1380 P=0.0054
Filaments (m3) 31.8±8 29.7±5 7.6±1 P=0.8230 P=0.0001
Zone II chondrocytes:
Numerical density (×104 cells/mm3) 0.53±0.04 0.48±0.04 0.86±0.07 P=0.6004 P=0.0001
Cell volume (m3) 802±35 801±34 867±58 P=0.9903 P=0.2811
RER (m3) 29.8±4 42.1±4 78.5±6 P=0.1466 P=0.0001
Golgi (m3) 12.3±1 12.0±2 49.4±8 P=0.9768 P=0.0001
Mitochondria (m3) 7.8±1 8.4±0.9 16.8±0.9 P=0.6896 P=0.0001
Lysosomes (m3) 4.5±0.3 4.3±0.9 1.9±0.3 P=0.8349 P=0.0002
Glycogen (m3) 32.9±6 30.4±9 21.4±5 P=0.8138 P=0.2041
Lipid vacuoles (m3) 12.1±3 15.9±4 7.5±3 P=0.5357 P=0.0730
Filaments (m3) 34.8±2 43.2±5 19.1±3 P=0.1416 P=0.0001
Mean value±standard error within each group of subjects and significance level.Discussion
The ability to perform repeated histological examinations
of the human cartilage tissue at the same site allowed a
detailed analysis of the tissue over time. Furthermore, it
may be pointed out that all the observations were per-
formed under blind conditions using, wherever possible, a
quantitative approach based on the estimation of the most
widely accepted parameters in the literature.
In agreement with already published data24,30, the data
presented here showed that in primary OA of the human
knee the articular cartilage was characterized by important
Osteoarthritis and Cartilage Vol. 9, No. 4 377Fig. 3. Ultrastructure of a chondrocyte from a normal subject (A) showing highly-developed RER and Golgi. In (B) is illustrated the
ultrastructural appearance of a chondrocyte from an osteoarthritic patient at baseline: the cytoplasm displays abundance of storage
structures (lipid vacuoles) and a few cell organelles. Six months after Hyaluronan treatment (C) chondrocytes from the same patient exhibit
changes toward normality in their ultrastructure.
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Change from baseline of the morphometric estimators describing the articular surface of the cartilage




RMS HA −1.11±0.5 P=0.0645 P=0.5326
MP −0.70±0.5 P=0.2754
Superficial amorphous layer:
Compactness (score) HA 0.70±0.22 P=0.0050 P=0.2710
MP 0.25±0.33 P=0.7580
Thickness (m) HA 0.28±0.06 P=0.0020 P=0.0190
MP 0.02±0.08 P=0.7340
Mean change from baseline±standard error within each group of subjects and significance level.Fig. 4. Numerical density of chondrocytes in zone I and zone II of the articular cartilage after treatment. Values are changes from
baseline±standard error. + =P<0.05, + + =P<0.01 (final vs baseline); *=P<0.10 (HA vs MP).structural modifications. Evidence of articular cartilage
degeneration includes the appearance of abnormal histo-
morphometric features such as increased surface rough-
ness with cleft formation and substantial disaggregation
of the amorphous protective layer covering the articular
surface. Furthermore, as previously reported in both
humans22 and in animal models of OA19, the baseline
cartilage biopsies from osteoarthritic patients exhibited a
significant reduction of the cell density, more pronounced in
the region proximal to the articular surface, and a sort of
metabolic switching of the surviving chondrocytes towards
a more catabolic activity, as indicated by the changes in the
ultrastructure of the cells27.
Adult articular cartilage has only a very limited capacity
of spontaneous repair. Such a capacity is limited to full-
thickness defects, while partial-thickness defects, anal-
ogous to the cleft and fissures seen during early stages of
human OA, do not heal spontaneously31.
Under appropriate conditions, however, a reduction of
the lesions was induced. Growth factors, such as IGF-I and
TGF-, proved to be useful32 in effecting some repair of
experimentally created partial-thickness defects. Radio-logical indications of some cartilage repair were found
in patients with severe ankle OA who underwent joint
distraction33, a treatment characterized by the absence of
mechanical stress and associated with an improvement of
chondrocyte metabolism34.
Intraarticular corticosteroids remain widely used for
symptomatic treatment of peripheral joint osteoarthritis.
Several studies in knee OA have indicated a significant
benefit compared with placebo, although they appear to
have no long-term effect35,36.
The quite positive results obtained in the MP treated
group of patients in some of the structural parameters we
measured are consistent with previously published data,
obtained in humans37 and in experimental models of
OA38–40. They indicated a protective effect of intra-articular
corticosteroids on cartilage lesions, but no significant
changes in the ultrastructural features of the chondrocytes.
It has been suggested41 that the capability of the corticos-
teroids to inhibit the stimulation of protease synthesis
induced by inflammatory cytokines could be the basis
of their beneficial effect when administered intra-
articularly.
Osteoarthritis and Cartilage Vol. 9, No. 4 379HA treatment, however, proved superior to steroid treat-
ment in almost all the morphometric estimators evaluated
in this study. The obtained results are consistent with
previously reported clinical data showing a reduction of
several markers of cartilage breakdown42 and a decrease
in extension and/or arthroscopic grading of the cartilage
lesions21,22 following intraarticular treatment with 500–
730 kDa hyaluronan.
An interesting finding of the present study was the
significant improvement of the cellular features. Six months
after treatment the number of viable chondrocytes was
significantly increased, approaching the value observed in
the normal control tissue even in the superficial and more
damaged region, whereas no changes of this parameter
were observed in the MP treated patients. More interest-
ingly, the cells appeared significantly improved in their
metabolism, showing a shift towards a more anabolic
activity, as indicated by the increased extension of the
synthetic cytocavitary network and mitochondria with
respect to the structures having catabolic or storage func-
tions. The observed reduction after HA treatment in the
presence of atypical pericellular matrix further supports this
improved metabolic activity of the chondrocytes.
Another finding of the present study was the significant
improvement, both in structure and thickness, of the super-
ficial amorphous layer of the cartilage 6 months after HA
treatment. Since this structure is mainly composed ofendogenous hyaluronic acid synthesized by the synovio-
cytes this result is consistent with previously reported data
indicating that HA treatment can lead to control of the
synovial membrane inflammation in terms of infiltration of
inflammatory cells and hyperplasia of the synovial lining22
and can also stimulate the neo-synthesis of hyaluronic acid
by the synoviocytes43.
Altogether the results obtained give further support to the
suggestion that intraarticular treatment with 500–730 kDa
HA may represent not only an efficacious symptomatic
treatment for osteoarthritis of the knee but also a candidate
for structure modification.Acknowledgments
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Changes in terms of modifications in the territorial matrix
appearance at month 6 compared with baseline
HA MP
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Improved 9 4
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